Qanxin Biotech

Quanxin Biotech is a clinical-stage biopharmaceutical company based in China, dedicated to the discovery and development of antibody-based therapies for autoimmune and allergic diseases. The company has built a comprehensive pipeline targeting key inflammatory pathways, including the Th17 and Th2 pathways, with candidates such as QX001N, QX002N, and QX005N. Its lead product, QX001N, is a biosimilar of ustekinumab developed in partnership with Huadong Medicine and has reached the BLA stage in China. Quanxin operates an integrated platform that encompasses the entire drug development process, from early-stage discovery to large-scale GMP manufacturing. The company is publicly listed on the Hong Kong Stock Exchange and aims to provide affordable, high-quality biologics to patients globally.